pancreatic cancer
Conditions
Interventions
Group A:Paclitaxel for injection (albumin-bound) 120mg/m^2, I.V., D1, D15, gemcitabine 1000mg/m^2, I.V., D1, D15, Q4w, 6 cycles.
Group B:Paclitaxel for injection (albumin-bound) 120mg/m^2, I.V., D1, D8, gemcitabine 1000mg/m^2, I.V., D1, D8, Q3w, 6-8 cycles.
Group C:Gemcitabine 1000mg/m^2, I.v.,.d1, D8, and sergio 60~100mg/d orally, twice a day, D1 ~14, Q3w, 6-8 cycles
Sponsors
Zhongshan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 70 years; 2.Patients with resectable pancreatic cancer confirmed by pathological examination; 3.Performance status ECOG=3 months; 5.Bone marrow function: neutrophils >=1.5x10^9/L, platelets >=100x10^9/L, hemoglobin >=90g/L; 6.Liver and kidney function: serum creatinine <=1.5 times the upper limit of normal value; AST and ALT<=2.5 times the upper limit of normal; Total bilirubin <=1.5 times normal upper limit; 7.Have good compliance with the planned treatment, understand the study process and sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1.Current or previous peripheral neuropathy of grade II or above; 2.Severe systemic infection or other serious systemic diseases; 3.Known to be allergic or intolerant to chemotherapeutic drugs or their excipients; 4.Has received anti-tumor therapy (chemotherapy, radiotherapy, immunotherapy) or any malignant tumor in the past 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer; 5.Pregnancy or lactation period, and the childbearing age of refusing to take appropriate contraceptive measures during the course of this study; 6.Participated in other research studies within 30 days before the first dose of study drug administration; Note: During screening, the investigator should ensure that the subject meets all the inclusion criteria. Subjects shall be excluded from the study if they meet the exclusion criteria due to changes (including laboratory results) in their condition after screening but before the first dose of the study drug has been administered.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactFan Yue
Zhongshan Hospital Affiliated to Fudan University
Outcome results
None listed